Procter & Gamble downgraded to In Line from Outperform at Evercore ISI

Evercore ISI downgraded Procter & Gamble to In Line from Outperform with a price target of $170, down from $190. Evercore expects a fiscal 2026 outlook with a “low but broad range” of scenarios to be issued on July 29 when Procter & Gamble reports Q4 results, the analyst tells investors in a research note. Macro pressures are transient, but the firm’s concern lies in adverse shifts in retail channels that challenge Procter’s growth potential, and could cap Procter’s sales growth below the 4% needed to drive operating leverage, the firm says.